Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

January 1, 2028

Conditions

Relapse Multiple MyelomaRefractory Multiple Myeloma

Interventions

DRUG

Talquetamab

Talquetamab will be administered subcutaneously.

DRUG

Ciltacabtagene Autoleucel

Ciltacabtagene Autoleucel will be administered intravenously.

Trial Locations (1)

Froedtert & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

lead

Medical College of Wisconsin

OTHER